IgG4-associated cholangitis (IAC) is an inflammatory disorder of the biliary tract representing a major manifestation of IgG4-related disease (IgG4-RD) often with elevation of serum IgG4 levels, infiltration of IgG4+ plasma cells in the affected tissue and good response to immunosuppressive treatment. Its first description may go back to 150 years ago. The clinical presentation of IAC is often misleading, mimicking other biliary diseases such as primary sclerosing cholangitis (PSC) or cholangiocarcinoma. The HISORt criteria - histopathological, imaging, and serological features (sIgG4), other organ manifestations of IgG4-RD and response to treatment - are the standard for the diagnosis of IAC. In this overview of a recent lecture, we summarize our original findings on IgG4-RD that (i) dominant IgG4+ B-cell clones identified by advanced next generation sequencing (NGS) are highly specific for IgG4-RD (meanwhile confirmed by others), are a highly accurate diagnostic marker to distinguish IgG4-RD from PSC and biliary/pancreatic malignancies and may be crucial in unravelling the pathophysiology of IgG4-RD; (ii) sIgG4/sIgG1 >0.24 have additional diagnostic value in comparison to sIgG4 in differentiating IAC from PSC; (iii) blood IgG4 mRNA is a highly accurate diagnostic marker comparable to NGS and may become an easily available and affordable diagnostic standard for distinguishing IgG4-RD from PSC and biliary/pancreatic malignancies; and (iv) ‘blue collar work' with long-term exposure to solvents, paints, oil products or industrial gases may be a risk factor for development of IgG4-RD. These findings may contribute to the understanding of the pathophysiology and to the early diagnosis and adequate treatment of IgG4-RD.

Keywords:
IgG4-related disease, Autoimmune pancreatitis, Primary sclerosing cholangitis, Cholangiocarcinoma, Next generation sequencing, Pancreatic carcinoma, Blue collar work
1.
Ghazale A, Chari ST, Zhang L, et al: Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008;134:706-715.
2.
Stone JH, Zen Y, Deshpande V: IgG4-related disease. N Engl J Med 2012;366:539-551.
3.
Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, et al: IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol 2015;48:198-206.
4.
de Buy Wenniger LJ, Culver EL, Beuers U: Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 2014;60:1453-1454.
5.
Kamisawa T, Funata N, Hayashi Y, et al: A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-984.
6.
Bartholomew LG, Cain JC, Woolner LB, Utz DC, Ferris DO: Sclerosing cholangitis: its possible association with Riedel's struma and fibrous retroperitonitis. Report of two cases. N Engl J Med 1963;269:8-12.
7.
Hoffmann CEE: Verschluss der gallenwege durch verdickung der wandungen. Arch Pathol Anat Physiol 1867;39:206-215.
8.
Tokala A, Khalili K, Menezes R, Hirschfield G, Jhaveri KS: Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol 2014;202:536-543.
9.
European Association for the Study of the Liver: EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-267.
10.
Oseini AM, Chaiteerakij R, Shire AM, et al: Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 2011;54:940-948.
11.
Boonstra K, Culver EL, de Buy Wenniger LM, et al: Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 2014;59:1954-1963.
12.
Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, et al: Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 2013;57:2390-2398.
13.
Hubers LM, Doorenspleet ME, Culver EL, et al: IgG4+ B-cell receptor clones in peripheral blood distinguish IgG4-associated cholangitis/autoimmune pancreatitis from primary sclerosing cholangitis. J Hepatol 2015;62:S233-S234.
14.
Mattoo H, Mahajan VS, Della-Torre E, et al: De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 2014;134:679-687.
15.
Vlachou PA, Khalili K, Jang HJ, Fischer S, Hirschfield GM, Kim TK: IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics 2011;31:1379-1402.
16.
Deshpande V, Zen Y, Chan JK, et al: Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-1192.
17.
Chari ST, Longnecker DS, Klöppel G: The diagnosis of autoimmune pancreatitis: a western perspective. Pancreas 2009;38:846-848.
18.
Shimosegawa T, Chari ST, Frulloni L, et al: International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas 2011;40:352-358.
19.
Buijs J, van Heerde MJ, Rauws EA, et al: Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas 2014;43:261-267.
20.
Carruthers MN, Topazian MD, Khosroshahi A, et al: Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74:1171-1177.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.